Kazakhstan starts preclinical trial of coronavirus vaccine
Kazakhstani scientists of the Research Institute of Biosafety Problems of the Science Committee under the Ministry of Education and Science of Kazakhstan have begun preclinical trials of an inactivated coronavirus vaccine, Strategy2050.kz reports with reference to the press service of the Ministry of Education and Science.
The inactivated vaccine was created on the basis of coronavirus-infected patient-derived virus strain. Minister of Education and Science Askhat Aimagambetov has congratulated the staff of the Research Institute.
“It is Kazakhstani science’s significant contribution to ensuring the biological safety of our state, as well as evidence of the country’s strong scientific potential. The staff of the Institute has once again shown its leading role in the development of new types of vaccines against dangerous and especially dangerous diseases”, the message reads.
It should be noted that the institute has already developed and introduced into production 67 types of vaccines against dangerous and especially dangerous diseases, 15 test systems and more than 30 biological products. Among them are vaccines against highly pathogenic avian influenza, highly pathogenic swine flu, nodular dermatitis, as well as a new vector vaccine against brucellosis.
